Welcome to Double Bond Pharmaceutical website. Our mission is to provide patients with more efficient and safer products in areas where their needs are not met. To this end, Double Bond Pharmaceutical’s scientific team has been working hard to overcome the drawbacks of widely available treatment options that have already proven their effectiveness. We focus on the redevelopment of known drugs by changing the route of administration to develop new formulations designed to reduce side effects and improve efficacy. Our vision is that medicines work best when they are delivered to the right place at the right time.

Welcome to Double Bond Pharmaceutical website. Our mission is to provide patients with more efficient and safer products in areas where their needs are not met. To this end, Double Bond Pharmaceutical’s scientific team has been working hard to overcome the drawbacks of widely available treatment options that have already proven their effectiveness. We focus on the redevelopment of known drugs by changing the route of administration to develop new formulations designed to reduce side effects and improve efficacy. Our vision is that medicines work best when they are delivered to the right place at the right time.

Our Products

At Double Bond Pharmaceutical, our areas of expertise are brain cancer, liver cancer and pneumonia. We have developed ways to treat these diseases much more effectively with our drug delivery system.

BRAIN CANCER

SI-053 is a temozolomide gel that is administered locally into the cavity created after resection of glioblastoma.

SI-053 is a temozolomide gel that is administered locally into the cavity created after resection of glioblastoma.

BRAIN CANCER

DRUG DELIVERY
SYSTEM

BeloGal® is a drug delivery system based on biomimetic encapsulation of the active pharmaceutical ingredient with a polymer- and biology-free excipient that radically increased the therapeutic effect while protecting the remaining healthy tissues from toxic effects.

BeloGal® is a drug delivery system based on biomimetic encapsulation of the active pharmaceutical ingredient with a polymer- and biology-free excipient that radically increased the therapeutic effect while protecting the remaining healthy tissues from toxic effects.

DRUG DELIVERY
SYSTEM

LIVER CANCER

SA-033 is a novel treatment of cancers in liver. It is the first drug candidate that our company has developed using our first-in-class technology BeloGal®, which enables direct targeting of a drug to the selected organ, which in the case of SA-033 means that doxorubicin is targeted directly to the liver.

SA-033 is a novel treatment of cancers in liver. It is the first drug candidate that our company DBP has developed using our first-in-class technology BeloGal®, which enables direct targeting of a drug to the selected organ, which in the case of SA-033 means that doxorubicin is targeted directly to the liver.

LIVER CANCER

PNEUMONIA

Belopenem is based on BeloGal® and selectively directs the broad spectrum antibiotic meropenem to the infected lungs of pneumonia patients.

Belopenem is based on BeloGal® and selectively directs the broad spectrum antibiotic meropenem to the infected lungs of pneumonia patients.

PNEUMONIA

Our Research

Please click on the link below to have a look at the current phase in our development.

Please click on the link below
to have a look at the current phase
in our development.

Our Latest News

Please click on the link below to find and read our latest reports.